Investing.com -- Medtronic plc (NYSE: MDT) shares have edged lower premarket on Wednesday following the company's latest quarterly results.

The company reported fourth quarter adjusted earnings per share of $1.55, topping the analyst estimate of $1.54 by $0.01, while revenue of $9.8 billion exceeded the consensus of $9.63 billion. However, shares slipped 0.8% as the company's fiscal 2027 earnings guidance fell short of Wall Street expectations.

The medical technology company posted fourth quarter revenue growth of 9.9% as reported and 6.6% organic, representing a 9.9% increase from $8.9 billion in the prior year period. For fiscal 2027, Medtronic issued adjusted EPS guidance of $5.90 to $6.00, with a midpoint of $5.95 that trails the analyst consensus of $6.06. The company projected organic revenue growth of 6.75% to 7.25% for the year ahead.

"Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor," said Geoff Martha, Medtronic chairman and chief executive officer.

The Cardiovascular Portfolio led fourth quarter performance with revenue of $3.8 billion, up 13.8% as reported and 10.1% organic, driven by high-teens growth in Cardiac Rhythm & Heart Failure. Cardiac Ablation Solutions revenue surged 78% globally, including 124% growth in the U.S., capturing an additional 8 points of U.S. market share. The Medical Surgical Portfolio grew 5.1% organically to $2.4 billion, while Neuroscience revenue increased 3.0% organically to $2.8 billion.

For the full fiscal year 2026, Medtronic generated revenue of $36.4 billion, up 8.4% as reported and 5.8% organically. Adjusted EPS for the year reached $5.53, representing 0.7% growth. The company produced operating cash flow of $7.3 billion and free cash flow of $5.4 billion, returning $4.2 billion to shareholders.

Medtronic also announced a dividend increase to $0.72 per share for the first quarter of fiscal 2027, marking the company's 49th consecutive year of dividend increases.